Aakash Desai: Interim Results from Our Phase 1 Trial of PDL1V, a Vedotin-Based ADC Targeting PD-L1 in R/R NSCLC at ASCO 2025 - OncoDaily Aakash Desai: Interim Results from Our Phase 1 Trial of PDL1V, a Vedotin-Based ADC Targeting PD-L1 in R/R NSCLC at ASCO 2025 / Aakash Desai, ADCs, ASCO 2025,

Interim Results from Our Phase 1 Trial of PDL1V, a Vedotin-Based ADC Targeting PD-L1 in R/R NSCLC at ASCO 2025 - Aakash Desai
@adesaimd.bsky.social

oncodaily.com/insight/aaka...

#ADCs #ASCO2025 #Cancer #NSCLC #OncoDaily #Oncology #PDL1Vtrial #Vedotin

Hidehito Horinouchi: Telisotuzumab Vedotin and Osimertinib in EGFR-Mutated NSCLC - OncoDaily Hidehito Horinouchi: Telisotuzumab Vedotin and Osimertinib in EGFR-Mutated NSCLC / Annals of Oncology, cancer, EGFR-mutated NSCLC, Hidehito Horinouchi, NSCLC,

Telisotuzumab Vedotin and Osimertinib in EGFR-Mutated NSCLC - Hidehito Horinouchi
@hhorinouchi.bsky.social

oncodaily.com/insight/hide...

#AnnalsOfOncology #Cancer #EGFRMutated #NSCLC #Health #OncoDaily #Oncology #Osimertinib #Medicine #Telisotuzumab #Vedotin